Table 1.

Risk of Stroke and Death Over 180 Days of Follow-up Among Adults Aged 65 Years or Older With Dual Enrollment in Medicare and Pharmacy Assistance Programs in New Jersey or Pennsylvania, 1994–2005

Outcome and Length of Follow-up, days	Full Cohort				Matched Cohort (1:1)
	SGA (n = 21,164)		FGA (n = 9,777)		FGA vs. SGA (n = 8,892 Pairs)
	No. of Events	Risk, %	No. of Events	Risk, %	Risk Ratioa	95% CI
Stroke
14	36	0.17	23	0.24	1.13	0.57, 2.20
30	80	0.38	54	0.55	1.31	0.85, 2.04
60	131	0.62	91	0.93	1.52	1.07, 2.15
120	220	1.04	135	1.38	1.44	1.09, 1.89
180	299	1.41	163	1.67	1.30b	1.02, 1.65
Death
14	213	1.01	140	1.43	1.22	0.93, 1.59
30	501	2.37	290	2.97	1.20	1.00, 1.44
60	1,004	4.74	570	5.83	1.20	1.06, 1.37
120	1,931	9.12	1,059	10.83	1.19	1.08, 1.30
180	2,764	13.06	1,442	14.80	1.12c	1.04, 1.20

Abbreviations: CI, confidence interval; FGA, first-generation antipsychotic drug; SGA, second-generation antipsychotic drug.

^a Estimated in the FGA versus SGA 1:1 propensity score–matched cohort unless otherwise noted (see Web Appendices 3 and 4 for details). The propensity model score included demographic characteristics, health services usage, comorbid chronic and psychiatric conditions, and concomitant medication use occurring before the index date, as listed in Web Table 1.

^b The corresponding risk ratio for stroke over 180 days of follow-up in the full cohort, estimated (as an odds ratio) via logistic regression with the same covariates used in the propensity score model, was 1.24 (95% CI: 1.01, 1.53).

^c The corresponding risk ratio for death over 180 days of follow-up in the full cohort, estimated via Poisson regression with the same covariates used in the propensity score model was 1.15 (95% CI: 1.08, 1.22). Nonparametric bootstrapping (n = 500 samples) was used to obtain the 95% confidence interval.